Oxazolidine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 6723 Experts worldwide ranked by ideXlab platform

Xinmiao Liang - One of the best experts on this subject based on the ideXlab platform.

Zhichao Jin - One of the best experts on this subject based on the ideXlab platform.

Tad H. Koch - One of the best experts on this subject based on the ideXlab platform.

  • correlation of in situ Oxazolidine formation with highly synergistic cytotoxicity and dna cross linking in cancer cells from combinations of doxorubicin and formaldehyde
    Journal of Medicinal Chemistry, 2016
    Co-Authors: Benjamin L Barthel, Erin L. Mooz, Laura Elizabeth Wiener, Gary G. Koch, Tad H. Koch
    Abstract:

    Anthracyclines are a class of antitumor compounds that are successful and widely used but suffer from cardiotoxicity and acquired tumor resistance. Formaldehyde interacts with anthracyclines to enhance antitumor efficacy, bypass resistance mechanisms, improve the therapeutic profile, and change the mechanism of action from a topoisomerase II poison to a DNA cross-linker. Contrary to current dogma, we show that both efficient DNA cross-linking and potent synergy in combination with formaldehyde correlate with the anthracycline’s ability to form cyclic formaldehyde conjugates as Oxazolidine moieties and that the cyclic conjugates are better cross-linking agents and cytotoxins than acyclic conjugates. We also provide evidence that suggests that the Oxazolidine forms in situ, since cotreatment with doxorubicin and formaldehyde is highly cytotoxic to dox-resistant tumor cell lines, and that this benefit is absent in combinations of formaldehyde and epirubicin, which cannot form stable Oxazolidines. These resul...

  • Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde
    2016
    Co-Authors: Benjamin L. Barthel, Erin L. Mooz, Laura Elizabeth Wiener, Gary G. Koch, Tad H. Koch
    Abstract:

    Anthracyclines are a class of antitumor compounds that are successful and widely used but suffer from cardiotoxicity and acquired tumor resistance. Formaldehyde interacts with anthracyclines to enhance antitumor efficacy, bypass resistance mechanisms, improve the therapeutic profile, and change the mechanism of action from a topoisomerase II poison to a DNA cross-linker. Contrary to current dogma, we show that both efficient DNA cross-linking and potent synergy in combination with formaldehyde correlate with the anthracycline’s ability to form cyclic formaldehyde conjugates as Oxazolidine moieties and that the cyclic conjugates are better cross-linking agents and cytotoxins than acyclic conjugates. We also provide evidence that suggests that the Oxazolidine forms in situ, since cotreatment with doxorubicin and formaldehyde is highly cytotoxic to dox-resistant tumor cell lines, and that this benefit is absent in combinations of formaldehyde and epirubicin, which cannot form stable Oxazolidines. These results have potential clinical implications in the active field of anthracycline prodrug design and development

Horacio F Olivo - One of the best experts on this subject based on the ideXlab platform.

Xiaoyan Luo - One of the best experts on this subject based on the ideXlab platform.